Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
The toxicity of rhenium and its compounds is not well documented. Elemental rhenium has been described as ‘relatively inert’ in the body. At the moment a price cannot be placed on Rhenium 188 because it is still in clinical trials. Testing facilities are needed to help with this process. Places like Columbia University and Cedar Sinai Medical Center are testing rhenium 188 now. Studies show Re- 188 is not expected to be hazardous for the environment.
Re-188 is a attractive radiopharmaceutical in skeletal metastases it emits beta particles that can be therapeutically benefital
Painful betastases of lung, prostate, breast, renal, and bladder cancers can be treated.
No sever side effects or hematopoictic toxicity
*80% of patients with bone pain, 77% with lung cancer, 80% with prostate cancer, 83% with breast cancer, 100% with bladder cancer, 50% with renal cancer, and 87% with other tumor types felt significant pain relief after one year of treatment.
Therefore Re-188 is a useful radiopharmaceutical to treat painful bone metastases from various tumor types.